Lung
carcinoma is the leading cause of
cancer-related death worldwide.
Chemotherapy remains the cornerstone of
lung cancer treatment. Unfortunately, most types of
cancer will develop resistance to
chemotherapies over the time. One of the efforts to prevent the
chemotherapy resistance is to find alternative
chemotherapy drugs.
Mogrol has been found to have antitumor activity. However, little is known about the pharmacological mechanisms underlying the suppression of
mogrol on
lung cancers. In this study, we observed that
mogrol exposure significantly reduced the
tumor volume and weight in
tumor-bearing nude mice without obvious effect on
body weight and cardiac function.
Mogrol also significantly inhibited the proliferation and migration of
lung cancer cells, including
non-small-cell lung carcinoma cells, A549, H1299, H1975 and SK-MES-1 cells, with no obvious effect on control human bronchial epithelial cells (HBE). Further studies revealed that
mogrol stirred excessive autophagy and autophagic flux, and finally, autophagic cell death, in
lung cancer cells, which could be attenuated by autophagy inhibitors, 3-MA and
chloroquine. Furthermore,
mogrol significantly activated AMPK to induce autophagy and autophagic cell death, which could be abrogated by Compound C, an AMPK inhibitor. In addition,
mogrol induced a significant increase in p53 activity in
lung cancer cells, accompanied with cell cycle arrest and apoptosis, which could be weakened by p53 silence. Our results indicated that
mogrol effectively suppressed
lung cancer cells in vivo and in vitro by inducing the excessive autophagy and autophagic cell death via activating AMPK signaling pathway, as well as cell cycle arrest and apoptosis via activating p53 pathway.